Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome

Single Oral Doses of ABX-1431 Demonstrate Statistically Significant Activity on Tourette Symptoms ABX-1431 Generally Safe and Well-Tolerated First Clinical Evidence of Positive Effect for ABX-1431, a First-in-Class Monoacylglycerol Lipase Inhibitor with Potential in Multiple Central Nervous System Diseases SAN DIEGO, November 28, 2017 /PRNewswire/ — Abide Therapeutics, a biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family …

Abide Therapeutics Announces Dosing of First Subject in Phase 1b Study of ABX-1431 in Patients with Neuromyelitis Optica (NMO)

Potential Therapy for Chronic Central Pain SAN DIEGO, Oct. 10, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor in patients with neuromyelitis optica (NMO) and related neuroinflammatory disorders associated with central pain. NMO is a …

Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer

SAN DIEGO, September 18, 2017/PRNewswire/ – Abide Therapeutics, a developer of innovative pharmaceuticals, announced today the appointment of Sapna Srivastava, Ph.D., to the position of Chief Financial and Strategy Officer. Dr. Srivastava brings to Abide more than 15 years of experience with a strong background in the biopharmaceutical industry and Wall Street. “At Abide Therapeutics we are absolutely committed to …

Abide Therapeutics to Present at EUFEMED Annual Meeting on ABX-1431 Clinical Program

SAN DIEGO, May 17, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today that new preclinical and clinical data on ABX-1431, an investigational monoacylglycerol lipase (MGLL) inhibitor, will be presented in a poster session at the European Federation for Exploratory Medicines Development Annual Meeting 2017 (EUFEMED), taking place in London, May 18-19, 2017. ABX-1431 is a first-in-mechanism, …

Abide Therapeutics Announces Dosing of First Subject in fMRI Imaging Study to Investigate Brain Activity Patterns Associated with ABX-1431

SAN DIEGO, May 10, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1 study using functional magnetic resonance imaging (fMRI) to evaluate patterns of neural activity in the brain associated with oral administration of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor, which modulates the activity of the endocannabinoid neurotransmitter …

Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America

SAN DIEGO, April 18, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor in patients with Tourette Syndrome (TS). TS is a neurodevelopmental disorder characterized by sudden, involuntary movements and/or sounds called tics. Additionally, Abide has …

Abide Therapeutics Announces First Patient Dosed in Phase 1b Study to Assess the Effect of ABX-1431 in Patients with Functional Dyspepsia

SAN DIEGO, December 14, 2016 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor, on gastric accommodation in patients with functional dyspepsia (FD), a gastrointestinal disorder characterized by altered gut motility and pain. “MGLL inhibitors have the …

Jason Clapper on “In vivo characterization of a selective monoacylglycerol lipase inhibitor ABD-1970 in rodents and activity in models of pain”

San Diego, Nov. 15, 2016 Abstract Monoacylglycerol lipase (MGLL) is the primary regulator of 2-arachidonoylglycerol (2-AG) an endogenous ligand of the cannabinoid (CB) receptors CB1 and CB2. Selective blockade of MGLL inhibits the hydrolytic degradation of 2-AG resulting in elevated 2-AG levels in the CNS and periphery, and CB1/2-dependent anti-nociceptive and anti-inflammatory effects. In the rodent brain and select peripheral …

Jackie Blankman at Society for Neuroscience “In vitro characterization of a selective monoacylglycerol lipase inhibitor ABD-1970 in human systems”

San Diego, November 15, 2016 Abstract Monoacylglycerol lipase (MGLL) is a serine hydrolase enzyme that converts monoacylglycerols into fatty acids and glycerol. The MGLL substrate 2-arachidonoylglycerol (2-AG) is an endogenous ligand of the cannabinoid receptors CB1 and CB2, which are the molecular targets of the psychoactive component of Cannabis sativa, Δ9tetrahydrocannabinol (THC). Inhibition or genetic inactivation of MGLL results in …

Abide Therapeutics Announces Celgene Option Exercise to Develop ABX-1431, an Investigational Endocannabinoid System Modulator for Patients with Neurological Diseases

SAN DIEGO, September 29, 2016 Abide Therapeutics announced today that Celgene has exercised its option to obtain ex-US rights to Abide’s first-in-class endocannabinoid system modulator, ABX-1431, for the potential treatment of neurological diseases. Celgene will be responsible for development costs for all indications from Phase 2 clinical trials and beyond. Abide retains US rights and will conduct a number of …